


# Monitoring frequent and high risk cannabis use

Danica Thanki and Eleni Kalamara General Population Surveys annual expert meeting Lisbon, 17 June 2014

# 2012 Problem drug use key epidemiological indicator revision: HIGH RISK DRUG USE



#### Monitoring of more intensive forms of cannabis use


Two complementary components:

Frequent cannabis use: defined by frequency of use "Use of cannabis daily, or almost daily, in the preceding 12 months" → 20+ days/last 30 days



High risk cannabis use: defined by (a proxy of) cannabis use disorders "Medical diagnosis according to current DSM or ICD criteria, e.g. cannabis harmful use or dependence or cannabis use disorder diagnosed in the past 12 months."  $\rightarrow$  CAST and its approximation of cannabis dependence

#### Daily or almost daily cannabis use in EU+



#### Monitoring of more intensive forms of cannabis use

Two complementary components:

Frequent cannabis use: defined by frequency of use "Use of cannabis daily, or almost daily, in the preceding 12 months" → 20+ days/last 30 days



High risk cannabis use: defined by (a proxy of) cannabis use disorders "Medical diagnosis according to current DSM or ICD criteria, e.g. cannabis harmful use or dependence or cannabis use disorder diagnosed in the past 12 months."  $\rightarrow$  CAST and its approximation of cannabis dependence

# New guidelines

### HOW & WHY

#### Isn't frequency of use enough?

20+ days in the last 30 days – useful, harmonised measure, substantiated by research

Still a lot of variation within the group of daily or near daily users

Additional level of risk, need for treatment – initiative from countries to use short instruments

Large validation study using cannabis disorders as a gold standard

#### Why cannabis dependence?

#### Concept of dependence:


- Central in research
- Good to excellent reliability in studies
- Validity confirmed by multi-method comparisons, longitudinal studies, latent variable analysis and construct validation studies
- Cross-cultural and some cross-species validity of the syndrome

Cannabis dependence: correlation with cannabis use-related problems, mental health problems and use of other substances

#### WHICH COUNTRIES?

# Precision of cannabis dependence prevalence estimate: Standard error / mean < 0.3 (Online calculator)

(US National Center for Health Statistics)



### WHICH SCALE?

# CAST and SDS tested in a large validation study (7 countries and 10 surveys) + published research

#### **CAST**

- better psychometric properties
- better predictor of cannabis dependence (we will see later)


### WHAT CUT-OFF POINT?

# Cut-off points and scales in low-prevalence conditions

Screening instruments as a rule overestimate prevalence at optimal cut-off points (best trade-offs between sensitivity and specificity) in situation of low prevalence (many more false positives than false negatives or low PPP)

→ Solution sought for this problem

### **Comparison of different estimates**



**Aim:** To predict cannabis dependence from CAST score AND from additional demographic/ drug use behaviour information

#### Model building:

- Outcome variable: cannabis dependence (Y/N) according to gold standard (MCIDI-CD3)
- Dependent variables: CAST score, study, country, prevalence, poly drug use, type of study (GPS or SPS\*), age, age at first use, gender// alcohol – smoking

Table: Logistic regression analysis for cannabis dependence				
	All studies	GPS	SPS	
	OR , {95%}	OR , {95%}	OR , {95%}	
CAST score (0-6)	2.37 {2.23,2.53 }	3.13 {2.48,3.96 }	2.30 {2.15,2.46 }	
Frequency of cannabis				
0 days	ref		ref	
1-3 days	1.18 {0.99,1.40 }		1.21 {1.00,1.46 }	
4-9 days	1.56{1.25,1.95}		1.56 {1.22,2.00 }	
10+ days	2.45{2.09,2.86}		2.46 {2.07,2.91 }	
Poly drug use				
0	ref		ref	
1-3	1.56{1.34,1.82}		1.52 {1.29,1.78 }	
4 or more	4.03 {2.58,6.29 }		4.75 {2.87,7.86 }	
Gender (ref:fem)	1.25 {1.02,1.54}	1.99{0.89,4.46}	1.21 {0.97,1.51 }	
Age!	1	0.97 {0.95,1.00}	1	
<18 yrs	ref			
18-25 yrs	0.84 {0.73,0.96 }			
25+ yrs	0.37 {0.27,0.49 }			
Gender x CAST score	0.85 {0.79,0.91 }	0.74{0.56,0.98}	0.86{0.79,0.93}	
Age at first use			0.95 {0.91,0.99 }	
<sup>!</sup> Age as continuous variable for the GPS only, Variables were not statistically significant in these models				

Table: Logistic regression analysis f	or cannabis dependence		
	All studies	GPS	SPS
	OR , {95%}	OR , {95%}	OR , {95%}
CAST score (0-6)	2.37 {2.23,2.53 }	3.13 {2.48,3.96 }	2.30 {2.15,2.46 }
Frequency of cannabis			
0 days	ref	7	ref
1-3 days	1.18 {0.99,1.40 }	More than 2-	1.21 {1.00,1.46 }
4-9 days	1.56{1.25,1.95}	folds increase by unit increase	1.56 {1.22,2.00 }
10+ days	2.45{2.09,2.86}	in CAST	2.46 {2.07,2.91 }
Poly drug use			
0	ref		ref
1-3	1.56{1.34,1.82}		1.52 {1.29,1.78 }
4 or more	4.03 {2.58,6.29 }		4.75 {2.87,7.86 }
Gender (ref:fem)	1.25 {1.02,1.54}	1.99{0.89,4.46}	1.21 {0.97,1.51 }
Age <sup>!</sup>	!	0.97 {0.95,1.00}	I I
<18 yrs	ref		
18-25 yrs	0.84 {0.73,0.96 }		
25+ yrs	0.37 {0.27,0.49 }		
Gender x CAST score	0.85 {0.79,0.91 }	0.74{0.56,0.98}	0.86{0.79,0.93}
Age at first use			0.95 {0.91,0.99 }
! Age as continuous variable for the GPS only, Variables were not statistically significant in these models			


Table: Logistic regression analysis for	or cannabis dependence		
	All studies	GPS	SPS
	OR , {95%}	011	OR , {95%}
CAST score (0-6)	2.37 {2.23,2.53 }	Odds of dependence	2.30 {2.15,2.46 }
Frequency of cannabis		increases with	
0 days	ref	increasing	ref
1-3 days	1.18 {0.99,1.40 }	frequency of drug	1.21 {1.00,1.46 }
4-9 days	1.56{1.25,1.95}	use 	1.56 {1.22,2.00 }
10+ days	2.45{2.09,2.86}		2.46 {2.07,2.91 }
Poly drug use			
0	ref		ref
1-3	1.56{1.34,1.82}		1.52 {1.29,1.78 }
4 or more	4.03 {2.58,6.29 }		4.75 {2.87,7.86 }
Gender (ref:fem)	1.25 {1.02,1.54}	1.99{0.89,4.46}	1.21 {0.97,1.51 }
Age!	1	0.97 {0.95,1.00}	!
<18 yrs	ref		
18-25 yrs	0.84 {0.73,0.96 }		
25+ yrs	0.37 {0.27,0.49 }		
Gender x CAST score	0.85 {0.79,0.91 }	0.74{0.56,0.98}	0.86{0.79,0.93}
Age at first use			0.95 {0.91,0.99 }
Age as continuous variable for the GPS only, Variables were not statistically significant in these models			

Table: Logistic regression analysis f	or cannabis dependence		
	All studies	GPS	SPS
	OR , {95%}	OR, {95%}	OR , {95%}
CAST score (0-6)	2.37 {2.23,2.53 }	3.13 {2.48,3.96}	2.30 {2.15,2.46 }
Frequency of cannabis			
0 days	ref		ref
1-3 days	1.18 {0.99,1.40 }		1.21 {1.00,1.46 }
4-9 days	1.56{1.25,1.95}	Odds of	1.56 {1.22,2.00 }
10+ days	2.45{2.09,2.86}	dependence	2.46 {2.07,2.91 }
Poly drug use		increases with	
0	ref	increasing number of drugs used	ref
1-3	1.56{1.34,1.82}		1.52 {1.29,1.78 }
4 or more	4.03 {2.58,6.29 }		4.75 {2.87,7.86 }
Gender (ref:fem)	1.25 {1.02,1.54}	1.99{0.89,4.46}	1.21 {0.97,1.51 }
Age <sup>!</sup>	1	0.97 {0.95,1.00}	!
<18 yrs	ref		
18-25 yrs	0.84 {0.73,0.96 }		
25+ yrs	0.37 {0.27,0.49 }		
Gender x CAST score	0.85 {0.79,0.91 }	0.74{0.56,0.98}	0.86{0.79,0.93}
Age at first use			0.95 {0.91,0.99 }
<sup>!</sup> Age as continuous variable for the GPS only, Variables were not statistically significant in these models			

Table: Logistic regression analysis f	or cannabis dependence		
	All studies	The effect of	gender is different
	OR , {95%}	depending on CAST score. More	
CAST score (0-6)	2.37 {2.23,2.53 }	specific, the odd of males being depended is higher that the one of	
Frequency of cannabis			v CAST scores and
0 days	ref	the association changes for higher	
1-3 days	1.18 {0.99,1.40 }	So	cores.
4-9 days	1.56{1.25,1.95}	-	1.56 {1.22,2.00 }
10+ days	2.45{2.09,2.86}		2.46 {2.07,2.91 }
Poly drug use			
0	ref	 70	ref
1-3	1.56{1.34,1.82}		1.52 {1.29,1.78 }
4 or more	4.03 {2.58,6.29 }		4.75 {2.87,7.86 }
Gender (ref:fem)	1.25 {1.02,1.54}	1.99{0.89,4.46}	1.21 {0.97,1.51 }
Age!	!	0.97 {0.95,1.00}	!
<18 yrs	ref		
18-25 yrs	0.84 {0.73,0.96 }		
25+ yrs	0.37 {0.27,0.49 }		
Gender x CAST score	0.85 {0.79,0.91 }	0.74{0.56,0.98}	0.86{0.79,0.93}
Age at first use			0.95 {0.91,0.99 }
! Age as continuous variable for the GPS only, \	/ariables were not statistically significant in th	ese models	

Table: Logistic regression analysis for	r cannabis dependence		
	All studies	GPS	SPS
	OR , {95%}	OR , {95%}	OR , {95%}
CAST score (0-6)	2.37 {2.23,2.53 }	3.13 {2.48,3.96 }	2.30 {2.15,2.46 }
Frequency of cannabis			
0 days	ref		ref
1-3 days	1.18 {0.99,1.40 }		1.21 {1.00,1.46 }
4-9 days	1.56{1.25,1.95}	Increasing age is associated with	1.56 {1.22,2.00 }
10+ days	2.45{2.09,2.86}	decreasing odds of	2.46 {2.07,2.91 }
Poly drug use		dependence.	
0	ref	1	ref
1-3	1.56{1.34,1.82}		1.52 {1.29,1.78 }
4 or more	4.03 {2.58,6.29 }		4.75 {2.87,7.86 }
Gender (ref:fem)	1.25 {1.02,1.54}	1.99{0.89,4.46}	1.21 {0.97,1.51 }
Age!	!	0.97 {0.95,1.00}	!
<18 yrs	ref /		
18-25 yrs	0.84 {0.73,0.96 }		
25+ yrs	0.37 {0.27,0.49 }		
Gender x CAST score	0.85 {0.79,0.91 }	0.74{0.56,0.98}	0.86{0.79,0.93}
Age at first use			0.95 {0.91,0.99 }
<sup>1</sup> Age as continuous variable for the GPS only, Va	riables were not statistically significant	in these models	

#### Comparison of different estimates



#### To summarize:

- Increasing CAST scores, frequency of use, number of drugs used are associated with higher odds of being dependent.
- Increasing age is associated with decreasing odds of being dependent
- There is an interaction between gender and CAST scores
- The model does not contradict with the published literature

#### **HOWEVER:**

- The model was the best one supported from the available data, but it is not the optimal.
- Countries should run their own models if the have the resources and they can use this only in lack of any other option

#### SDS

- Not as good psychometric properties as CAST
- Poorer predictor of cannabis dependence than CAST in our study
- However, similar associations were apparent (with the exception gender/ gender\*SDS) and a formula can also be provided for countries that have only SDS

#### Content of the guidelines

- Rationale explanation, different concepts and literature overview (with short scales)
- Assets and drawbacks explained
- Guidelines of scale translation and adaptation
- National validation study guidelines (if decided)
- Practical issues of using scales (placement in the questionnaire, suggested codebook and SPSS syntaxes, formula to estimate prevalence of cannabis dependence)
- Interpretation of the results obtained, limitations

#### Conclusion

To apply CAST if prevalence vs. sample size allows (own validation study would give even more precise results but can be relatively costly)

#### Reporting in form of both:

- raw CAST results and
- estimate of cannabis dependence prevalence

Future: evaluation of translation into policy making – GPS results vs. cannabis treatment demand and offer

Long-term: update of standards when and if needed